BioMarin Pharmaceutical Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (34)

Latest Posts

About This Stock More About This Stock
BioMarin Bounces Back With Solid Q2 Earnings, Nudges Up 2021 Guidance
Article By: Benzinga
Thursday, July 29, 2021 10:49 AM EDT
BioMarin Pharmaceutical Inc reported a 17% Y/Y increase in revenue to $501.7 million in Q2, beating the consensus of $448.8 million, attributable to Vimizim, Naglazyme, and Palynziq product revenues, partially offset by lower Kuvan product revenues. 
In this article: BMRN
Read
Apple Becomes First Ever $2trn Company But Markets Wobble On Fed Uncertainty
Article By: Adam Vettese
Thursday, August 20, 2020 6:12 AM EDT
Markets pulled back overnight in the US and Asia, with futures indicating more losses are likely today, after a lack of clear policy direction from the Fed triggered some profit taking.
In this article: EL, IAG, TGT, BTDPF, CTAGF, ESYJY, HCHDF, PSMMF, BMRN, AAPL, BIIB, GILD, ROST, DIA, SPY, COMP, BABA, SPX, LYFT, UBER, ARGGY, WZZAF, GCPSF
Read
EC Top Precision Medicine Stocks
Article By: Fred Fuld
Sunday, January 19, 2020 1:13 PM EDT
In precision medicine, the focus is on identifying which approaches will be effective for which patients based on genetic, environmental, and lifestyle factors. For investors, there are a few stocks that participate in this industry.
In this article: BMRN, ILMN, VRTX, VRML, CNCR, IQV
Read
Biotech (Top 30 Weights) 2019 Earnings Estimates Up 8.58% In Last 2 Months
Article By: T.J. Hayes
Monday, September 9, 2019 7:36 PM EDT
The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.
In this article: ALNY, ALXN, BMRN, CBPO, ILMN, INCY, JAZZ, REGN, SGEN, AMGN, BIIB, CELG, EXEL, GILD, HZNP, MYL, NBIX, TECH, VRTX, AMRN, SAGE, GWPH, SRPT, BLUE, NVCR, IONS, BGNE, PRAH, SYNH, IBB
Read
3 Biotech Stocks Up In The Past Month On Industry Turnaround
Article By: Zacks Investment Research
Tuesday, June 5, 2018 1:08 PM EDT
After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front.
In this article: BMRN, LGND, VVUS Also: JNJ
Read

Latest Tweets for $BMRN

No tweets yet!